Myriad Genetics, Inc.
MYGN
$6.61
-$0.18-2.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.83% | 7.38% | 11.21% | 12.15% | 14.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.83% | 7.38% | 11.21% | 12.15% | 14.78% |
| Cost of Revenue | -0.81% | 3.19% | 6.77% | 11.20% | 12.16% |
| Gross Profit | 5.90% | 9.28% | 13.23% | 12.57% | 16.00% |
| SG&A Expenses | -1.93% | -0.07% | -0.16% | -3.10% | -2.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.44% | 3.54% | 4.41% | 2.00% | 2.36% |
| Operating Income | 25.85% | 22.34% | 34.01% | 42.76% | 44.37% |
| Income Before Tax | -168.39% | 46.11% | 52.94% | 58.65% | 40.91% |
| Income Tax Expenses | -1,692.86% | -2,733.33% | 254.55% | 92.11% | 91.67% |
| Earnings from Continuing Operations | -154.64% | 56.78% | 51.65% | 57.73% | 37.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.64% | 56.78% | 51.65% | 57.73% | 37.47% |
| EBIT | 25.85% | 22.34% | 34.01% | 42.76% | 44.37% |
| EBITDA | 63.88% | 53.14% | 65.32% | 69.74% | 61.17% |
| EPS Basic | -137.30% | 60.45% | 56.19% | 61.33% | 40.77% |
| Normalized Basic EPS | 29.09% | 29.26% | 43.45% | 48.48% | 48.19% |
| EPS Diluted | -136.56% | 60.47% | 56.18% | 61.20% | 40.56% |
| Normalized Diluted EPS | 29.09% | 29.26% | 43.45% | 48.48% | 48.19% |
| Average Basic Shares Outstanding | 4.99% | 7.18% | 9.52% | 9.53% | 7.16% |
| Average Diluted Shares Outstanding | 4.99% | 7.18% | 9.52% | 9.53% | 7.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |